GSKure

Company Overview

Snapshot

Founded in January 2016 by Hagit Eldar- Finkelman, Ph.D., GSKure operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing innovative drug candidates. In February 2016, GSKure was part of the first class of neurotech startups to graduate from Brainnovations.

Business overview

GSKure is an IP-based company focused on developing innovative proprietary GSK-3 peptide inhibitor drug candidates. The company's Kure products are designed to target a unique region at the GSK-3 protein surface, specifically the substrate binding site, offering substrate-competitive inhibitors (SCIs) with improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors. GSKure's novel SCI strategy aims to provide significant advantages for clinical practice, primarily serving the pharmaceutical and biotechnology industries with a focus on patients in the United States.

Strategic signal

In February 2016, GSKure was recognized as one of the first neurotech startups to graduate from the Brainnovations program. This early validation highlights the company's potential in the neurogenetic disorders space and signals a strong foundation for its drug discovery and development efforts.

Company Intelligence Q&A

Who founded GSKure?

GSKure was founded by Hagit Eldar- Finkelman, Ph.D.

When was GSKure founded?

GSKure was founded in January 2016.

What is GSKure's primary focus?

GSKure focuses on developing innovative proprietary GSK-3 peptide inhibitor drug candidates for treating neurogenetic disorders.

What is the product stage of GSKure's offerings?

GSKure's products, including Kure, are currently in the R&D stage, as indicated by the company's product stage information.

What significant milestone did GSKure achieve in early 2016?

In February 2016, GSKure was among the first class of neurotech startups to graduate from the Brainnovations program.